Skip to main content
. 2022 Aug 1;13:953721. doi: 10.3389/fimmu.2022.953721

Figure 4.

Figure 4

Implications of MTAP/CDKN2A MUT in prognosis, clinicopathological features, and sensitivity to therapy of 3,563 patients with RCC from the Western cohort. (A) Classified by the MTAPMUT , DSS, PFS, DFS, and OS of RCC patients from the Western cohort using Kaplan–Meier survival analysis and log-rank test. (B) Classified by the CDKN2AMUT , DSS, PFS, DFS, and OS of RCC patients from the Western cohort using Kaplan–Meier survival analysis and log-rank test. ****, P<0.0001.